© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Physicians assess bone mineral density (BMD) to monitor the impact of cancer therapy—especially hormone modifying treatments and aromatase inhibitors—on patients’ bones over time, and to diagnose osteoporosis and determine who should be treated for it.
To monitor the impact of cancer therapy on patients’ bones over time, and to diagnose osteoporosis and determine who should be treated for it, clinicians assess bone mineral density (BMD), or mass relative to volume
The most common measure of BMD is dual-energy X-ray absorptiometry, or DEXA, a quick, simple, and painless procedure that typically involves two-dimensional X-ray scans of the lower spine and hips while the patient lies face-up on a cushioned table. DEXA is considered the gold standard because of its low-dose radiation exposure, precision, and moderate cost.
Julie Gralow, MD, a medical oncologist at the University of Washington in Seattle, says “in a perfect world,” the patient receives a DEXA scan at the beginning of cancer treatment for a baseline measurement, and then another about a year later. Partly because bone tissue changes slowly, the American Society of Clinical Oncology does not recommend more frequent DEXA scans, Dr. Gralow says.
Magnetic resonance imaging, which produces images of body structures using magnetism, radio waves, and a computer, helps clinicians examine the minutiae of bone architecture, including vascular structure and nerves. But this expensive technique isn’t a definitive measure of bone loss, and its use for that purpose is experimental.
Doctors can also employ other options, including a simple urine or blood test to check for substances that can indicate the patient is quickly losing bone calcium.
Understanding the Cancer Experience From the Outside Looking In
Educated Patient® Breast Cancer Summit at MBCC Treating Brain Metastases Presentation: March 4, 2023
Kisqali Plus Endocrine Therapy May Reduce Breast Cancer Recurrence Risk
Rybrevant Is Efficacious, Tolerable in EGFR Exon 20-Mutant Lung Cancer